Acute exacerbations represent critical inflection points in the clinical trajectory of chronic obstructive pulmonary disease. When pulmonary hypertension complicates these episodes, morbidity and mortality increase substantially. However, clinicians often face significant challenges when identifying secondary pulmonary vascular disease in emergency settings. Recent investigative evidence highlights the emerging utility of serum HMGB1 in AECOPD as a surrogate biomarker for vascular remodeling and heightened systemic inflammation. High-mobility group box 1 functions as a typical damage-associated molecular pattern protein. When damaged parenchymal and endothelial cells release this molecule, it actively triggers severe inflammatory cascades. Consequently, measuring this alarmin provides valuable diagnostic clarity, helping physicians distinguish uncomplicated exacerbations from those driven by severe cardiopulmonary compromise.

Understanding the Role of Serum HMGB1 in AECOPD Pathophysiology

High-mobility group box 1 normally resides inside cellular nuclei, where it coordinates structural DNA organization and regulates transcriptional activity. However, acute cellular stress, hypoxia, and tissue necrosis cause cells to translocate and release this protein into extracellular spaces. In respiratory diseases, necrotic structural cells and activated neutrophils actively secrete this molecule into the systemic circulation. Therefore, measuring serum HMGB1 in AECOPD reflects both intense airway inflammation and secondary pulmonary vascular injury. Once released, the protein binds to high-affinity receptors, including the receptor for advanced glycation end products and toll-like receptor 4. This receptor engagement activates downstream nuclear factor kappa B pathways, which accelerate inflammatory mediator transcription. Consequently, pulmonary artery smooth muscle cells proliferate rapidly, leading to progressive medial hypertrophy and lumen narrowing. In patients experiencing severe exacerbations, hypoxemia amplifies this damage loop. As a result, the lung microvasculature undergoes structural remodeling, elevating pulmonary vascular resistance and predisposing susceptible individuals to right ventricular overload.

Diagnostic Utility of Serum HMGB1 in AECOPD with Pulmonary Hypertension

Differentiating patients with concurrent pulmonary vascular elevation during an exacerbation remains clinically difficult because symptoms overlap significantly. A recent single-centre clinical study evaluated 127 hospitalized patients, categorizing them into non-pulmonary hypertension and pulmonary hypertension cohorts. Notably, serum HMGB1 concentrations were markedly higher in individuals presenting with concurrent pulmonary hypertension than in those without vascular involvement. Receiver operating characteristic analyses confirmed that circulating HMGB1 reliably predicts elevated pulmonary arterial pressures. Furthermore, multiple logistic regression demonstrated that this alarmin serves as an independent predictor of vascular decompensation. Standard diagnostic pathways rely heavily on transthoracic echocardiography, which frequently yields poor acoustic windows in hyperinflated chest cavities. In contrast, circulating biomarkers provide objective, rapid physiological data at bedside. Therefore, integrating this molecular assay into routine admission panels enhances early detection of secondary vascular complications before overt right heart failure becomes clinically irreversible.

Interplay Between HMGB1, Endothelin-1, and Hypercapnia

Pulmonary vascular remodeling rarely proceeds through isolated biochemical pathways during acute exacerbations. Instead, it involves intricate crosstalk between inflammatory alarmins, potent endogenous vasoconstrictors, and altered blood gas parameters. The study highlighted that circulating endothelin-1 and arterial carbon dioxide tension increase significantly alongside HMGB1. Endothelin-1 acts as a powerful vasoconstrictive peptide that promotes robust vascular smooth muscle mitogenesis. When clinicians combined serum HMGB1, endothelin-1, and PaCO2, the diagnostic accuracy for identifying pulmonary hypertension reached an area under the curve of 0.751. This multimarker approach demonstrates superior discriminatory performance compared with individual laboratory parameters alone. Additionally, severe hypercapnia worsens pulmonary vasoconstriction by altering local vascular tone and inducing intracellular acidosis. Consequently, elevated PaCO2 acts synergistically with inflammatory alarmins to aggravate vascular strain. Evaluating these parameters collectively provides critical insight into the severity of ventilation-perfusion mismatch and pulmonary circulatory impairment.

Correlation with Cytokine Profiles and Microvascular Signaling

Circulating alarmin concentrations also demonstrate distinct correlations with classical inflammatory cytokines and angiogenic factors. Specifically, serum HMGB1 levels correlate positively with interleukin-6 and tumour necrosis factor-alpha concentrations. These pro-inflammatory cytokines perpetuate systemic inflammation and drive endothelial dysfunction during acute episodes. Conversely, HMGB1 exhibits a significant negative correlation with vascular endothelial growth factor. Under physiological conditions, vascular endothelial growth factor maintains microvascular endothelial cell survival and supports capillary integrity. When intense inflammation suppresses this signaling, endothelial cell apoptosis accelerates, destabilizing pulmonary capillary beds. Moreover, unrestrained HMGB1 release sustains this destructive cycle by recruiting additional inflammatory leukocytes into the lung parenchyma. Consequently, the balance between angiogenic survival cues and pro-inflammatory alarmins shifts unfavorably. This biological disruption explains why patients with high alarmin burdens experience more pronounced microvascular degradation and accelerated functional decline during exacerbations.

Risk Stratification and Clinical Decision-Making

Effective risk stratification in acute cardiopulmonary admissions enables clinicians to allocate intensive monitoring resources efficiently. In clinical cohorts, a serum HMGB1 cutoff value of 38.24 ng/mL successfully identified intermediate-to-high risk pulmonary hypertension. This specific threshold yielded a sensitivity of 69.2%, a specificity of 64.7%, and an area under the curve of 0.700. Therefore, identifying patients above this cutoff allows medical teams to anticipate acute right ventricular decompensation proactively. Clinicians can adjust non-invasive ventilation strategies, optimize diuretic therapy, and avoid aggressive fluid resuscitation that might compromise right ventricular function. However, clinicians must recognize that these findings apply specifically to acute exacerbations. Because systemic inflammation peaks during acute hospitalizations, these biomarker thresholds should not be directly extrapolated to stable-phase disease. Further longitudinal investigations remain necessary to determine whether persistent biomarker elevation after discharge heralds permanent pulmonary vascular remodeling.

Frequently Asked Questions

What is the primary role of HMGB1 in COPD exacerbations?

High-mobility group box 1 acts as a nuclear protein that damaged cells release during severe tissue stress. In acute exacerbations, extracellular HMGB1 acts as a potent pro-inflammatory alarmin. It stimulates pattern recognition receptors, triggers downstream inflammatory cascades, and accelerates pulmonary vascular remodeling. Consequently, elevated circulating levels indicate severe parenchymal necrosis, intense systemic inflammation, and increased risk of acute pulmonary vascular complications.

How does combining HMGB1 with other markers improve diagnostic accuracy?

Combining HMGB1 with endothelin-1 and PaCO2 creates a comprehensive biomarker panel that reflects inflammation, active vasoconstriction, and respiratory failure simultaneously. While individual markers provide moderate diagnostic utility, their combined model achieved a superior area under the curve of 0.751 for identifying secondary pulmonary hypertension. This synergistic approach significantly reduces diagnostic uncertainty when traditional echocardiographic imaging remains technically difficult or inconclusive.

Can HMGB1 levels guide long-term therapy for stable COPD patients?

Current clinical evidence validates HMGB1 risk stratification exclusively within the acute exacerbation setting. Because systemic inflammatory responses fluctuate dynamic during acute illness, these specific cutoff values cannot be applied to stable outpatients. Clinicians require further prospective, multi-centre studies in stable cohorts to determine whether baseline HMGB1 levels reliably predict long-term pulmonary vascular disease progression or guide targeted pharmacotherapy.

Disclaimer: This content is for informational and educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Lv Q et al. Utility of serum HMGB1 in chronic obstructive pulmonary disease with pulmonary hypertension: A single-centre analysis. Pulmonology. 2026 Dec undefined. doi: 10.1080/25310429.2026.2720837. PMID: 42625546.

2. Ferhani N et al. Expression of high-mobility group box 1 and of its receptors in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(9):917-927.

3. Goldenberg NM et al. High-mobility group box-1 induces vascular remodelling processes via c-Jun activation. Br J Pharmacol. 2019;176(18):3627-3640.